Advice
following an abbreviated submission:
ciclosporin (Cequa®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of moderate-to-severe Dry Eye Disease (keratoconjunctivitis sicca) in adult patients who have not responded adequately to artificial tears.
SMC restriction: severe keratitis in adult patients with Dry Eye Disease.
Cequa® is a new formulation of ciclosporin eye drops, with limited net budget impact.
Download detailed advice246KB (PDF)
Medicine details
- Medicine name:
- ciclosporin (Cequa)
- SMC ID:
- SMC2739
- Indication:
Treatment of moderate-to-severe Dry Eye Disease (keratoconjunctivitis sicca) in adult patients who have not responded adequately to artificial tears.
- Pharmaceutical company
- Sun Pharmaceuticals UK Ltd
- BNF chapter
- Eye
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 13 January 2025